KR101359806B1 - Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same - Google Patents

Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same Download PDF

Info

Publication number
KR101359806B1
KR101359806B1 KR1020120058747A KR20120058747A KR101359806B1 KR 101359806 B1 KR101359806 B1 KR 101359806B1 KR 1020120058747 A KR1020120058747 A KR 1020120058747A KR 20120058747 A KR20120058747 A KR 20120058747A KR 101359806 B1 KR101359806 B1 KR 101359806B1
Authority
KR
South Korea
Prior art keywords
extract
potato
cudrania
leaf
complex extract
Prior art date
Application number
KR1020120058747A
Other languages
Korean (ko)
Other versions
KR20130134882A (en
Inventor
박철수
황지영
최성원
Original Assignee
광동제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 광동제약 주식회사 filed Critical 광동제약 주식회사
Priority to KR1020120058747A priority Critical patent/KR101359806B1/en
Publication of KR20130134882A publication Critical patent/KR20130134882A/en
Application granted granted Critical
Publication of KR101359806B1 publication Critical patent/KR101359806B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38Other non-alcoholic beverages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/60Moraceae (Mulberry family), e.g. breadfruit or fig
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00Processes
    • A23V2300/14Extraction
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00Processes
    • A23V2300/48Ultrasonic treatment
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 혈당강하에 효능이 있는 돼지감자 및 꾸지뽕잎의 복합추출물에 관한 것으로, 본 발명의 복합추출물은 돼지감자 및 꾸지뽕잎의 함량을 각각의 함량에 비하여 3/10 내지 7/10의 양을 함유하더라도 상승작용에 의해 혈당강하 효과가 매우 뛰어나 당뇨병 치료제로 개발 될 수 있을 뿐만 아니라, 당뇨병 관련 질환의 혈당 개선을 위한 건강기능식품에 이용될 수 있다.The present invention relates to a complex extract of pork potato and courageous leaf extract, which is effective in lowering blood sugar, and the complex extract of the present invention has an amount of 3/10 to 7/10 compared to the respective contents of the pork potato and jacuzzi leaf. Even if it contains, the synergistic effect is excellent in hypoglycemic effect can not only be developed as a diabetes treatment, but also can be used in health functional food for improving blood sugar of diabetes-related diseases.

Description

혈당강하에 효능이 있는 돼지감자 및 꾸지뽕잎의 복합추출물 및 이를 이용한 건강기능식품 조성물 {Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same}Combined extract of pork potato and Cudrania leaf efficacious in reducing blood sugar and health functional food composition using the same {Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same}

본 발명은 혈당강하에 효능이 있는 돼지감자(Helianthus tuberous) 및 꾸지뽕잎(Cudrania tricuspidata)의 복합추출물 및 이를 이용한 건강기능식품 조성물에 관한 것이다.
The present invention is a pig potato ( Helianthus) effective in lowering blood sugar tuberous ) and Cudrania leaves tricuspidata ) relates to a complex extract and a dietary supplement composition using the same.

서구화된 식습관과 생활양식의 변화 및 고령화 사회가 도래 하면서 암, 뇌혈관질환, 심장질환 등 각종 성인병이 증가하고 있는 추세이다. 그 중 당뇨병은 유병율이 꾸준히 증가하고 있으며, 급성 및 만성 합병증뿐만 아니라 사망률이 높아 국민건강을 위협하고 있다. 당뇨병은 인슐린의 분비량이 부족하거나 정상적인 기능이 이루어지지 않는 대사질환의 일종으로, 혈중 포도당의 농도가 높아지는 고혈당이 나타나고, 소변으로 포도당을 배출하게 되는 질병으로 크게 췌장 β-세포의 파괴에 의한 인슐린 결핍으로 발생하는 제1형 당뇨병과 인슐린 분비 및 작용의 결함에 의해 발생하는 제2형 당뇨병으로 나눌 수 있다. 이러한 당뇨병에 있어서 췌장 β-세포는 인슐린을 분비하여 혈당을 조절하고, 인슐린 수용체가 존재하여 인슐린 신호전달에 중요한 역할을 담당하고 있으며, 최근 β-세포의 성장과 증식이 당뇨병의 치료와 예방에 영향이 있다는 연구가 보고되고 있다.
With the advent of westernized eating habits, lifestyle changes, and aging societies, various adult diseases such as cancer, cerebrovascular disease, and heart disease are increasing. Among them, the prevalence of diabetes is steadily increasing, and high mortality as well as acute and chronic complications threaten national health. Diabetes is a type of metabolic disease in which insulin secretion is insufficient or does not function normally. Hyperglycemia occurs due to high glucose levels in the blood, and glucose is released into the urine. Insulin deficiency is caused by the destruction of the pancreatic β-cells. It can be divided into type 1 diabetes caused by type 2 diabetes caused by defects in insulin secretion and action. In this diabetes, pancreatic β-cells secrete insulin to regulate blood sugar, insulin receptors are present and play an important role in insulin signaling. Recently, the growth and proliferation of β-cells affect the treatment and prevention of diabetes. Studies have been reported.

우리나라의 경우 인슐린 비의존형의 제2형 당뇨환자가 전체 당뇨환자의 90-95%를 차지하고 있으며 대부분 약물요법으로 혈당을 조절하고 있으나 시간이 경과함에 따라 점점 많은 양의 약물 복용이 요구되므로 부작용이 많기 때문에 이를 예방하기 위해 천연물질로부터 당뇨 개선 기능을 가진 활성 물질의 발굴과 제품 개발의 중요성이 강조되고 있다.
In Korea, insulin-independent type 2 diabetic patients account for 90-95% of all diabetic patients, and most of them control blood sugar by pharmacotherapy, but more and more side effects are required as time passes. Therefore, in order to prevent this, the importance of the discovery of active substances with diabetes improvement function and product development is emphasized.

돼지감자(Helianthus tuberous)는 "뚱단지"라고도 불리는 국화과의 다년생 식물로서 그의 뿌리인 구경을 가리킨 경우도 있다. 원산지는 캐나다 동부 및 미국의 북동부이다. 땅속줄기의 끝이 굵어져서 덩이줄기가 발달한다. 줄기는 곧게 서고 가지가 갈라지며 높이가 1.5∼3m이고 센털이 있다. 잎은 줄기 밑 부분에서는 마주나고 윗부분에서는 어긋나며 긴 타원 모양이고 끝이 뾰족하며 가장자리에 톱니가 있고 밑 부분이 좁아져 잎자루로 흘러 날개가 된다. 덩이줄기는 길쭉한 것에서 울퉁불퉁한 것까지 모양이 매우 다양하고 크기와 무게도 다양하다. 덩이줄기 껍질 색깔도 연한 노란 색·갈색·붉은 색·자주색으로 다양한데, 껍질이 매우 얇아 건조한 공기에 노출하면 금방 주름이 지고 속살이 파삭해진다. 덩이줄기를 식용으로 재배하였으나 지금은 인가 근처에서 야생으로 자라며 일부에서는 가축의 사료로 쓰기 위해 심기도 한다. 한방에서는 뿌리를 국우(菊芋)라는 약재로 쓰는데, 해열 작용이 있고 대량 출혈을 그치게 한다.
Pork Potato ( Helianthus tuberous ) is a perennial plant of the Asteraceae, also called "fatty", sometimes referring to its root, caliber. Country of origin is eastern Canada and northeastern United States. The end of the underground stem is thickened and tubers develop. Stems stand upright, branches are split, height is 1.5 ~ 3m, and there are centriles. The leaves face at the bottom of the stem, are displaced at the top, have a long oval shape, pointed ends, serrated at the edges, and narrow at the bottom to flow into the petioles, becoming wings. Tubers vary in shape from elongated to rugged and vary in size and weight. Tuber shell color also varies from light yellow to brown to red to purple. The skin is so thin that when exposed to dry air, it quickly creases and crusts. Tubers are cultivated for food use, but now they grow wild near permits, and some are planted for livestock feed. In oriental medicine, the root is used as a medicine called gukwoo (菊芋), fever is an action that stops bleeding mass.

또한 최근에 돼지감자의 덩기줄기에 당뇨병 치료 및 합병증 예방에 탁월한 효과가 있어 천연 인슐린이라 불리는 이눌린을 약 15% 이상 함유하고 있는 사실이 나타나면서 다양한 연구가 진행되고 있다. 먼저, 대한민국 공개특허 제2010-33064호에는 돼지감자 추출물을 유효성분으로 포함하는 비만 또는 제2형 당뇨병의 예방 또는 개선용 조성물을 개시하고 있다. 또한 대한민국 공개특허 제2006-41438호, 제2003-26384호 및 제2012-14744호에서는 돼지감자 분말 또는 추출물을 포함하면서 추가적으로 오미자, 대추, 인삼 및 상엽 분말 또는 추출물을 추가하여 당뇨에 효과를 나타냄을 기재하고 있다. 하지만, 이러한 문헌에 나타난 혈당강하 효과는 비교적 탁월한 효과를 나타내고 있지 않다. 따라서 현재에도 돼지감자를 이용한 다양한연구가 진행되고 있다.
In recent years, various studies have been carried out with the fact that the pork stem has an excellent effect on the treatment of diabetes and prevention of complications, containing about 15% or more of inulin called natural insulin. First, Korean Unexamined Patent Publication No. 2010-33064 discloses a composition for preventing or improving obesity or type 2 diabetes, including a pig potato extract as an active ingredient. In addition, Korean Patent Laid-Open Publication Nos. 2006-41438, 2003-26384, and 2012-14744 include the addition of Schisandra potato, jujube, ginseng, and upper leaf powder or extract, showing the effect on diabetes. It is described. However, the hypoglycemic effect shown in these documents does not show a relatively excellent effect. Therefore, a variety of studies are still underway using pig potatoes.

쌍떡잎식물 쐐기풀목 뽕나무과의 낙엽활엽 소교목에 속하는 꾸지뽕(Cudrania tricuspidata)은 굿가시나무라고도 한다. 산기슭의 양지쪽이나 마을 부근에서 자란다. 가지에 가시가 있고, 잎은 3갈래로 갈라진 것과 가장자리가 밋밋하고 달걀 모양인 것이 있다. 3갈래로 갈라지는 잎은 끝이 둔하고 밑이 둥글다. 달걀 모양의 잎은 끝과 밑이 뾰족하고 길이 6∼10cm, 폭 3∼6cm로 표면에 잔털이 있으며 뒷면에는 융모(絨毛:길이가 일정하지 않은 털이 서로 엉킨 것)가 있다. 잎자루의 길이는 15∼25mm로 털이 있다. 잎은 뽕잎 대용으로 쓰고, 열매는 먹을 수 있으며 잼을 만들거나 술을 담그고, 나무껍질과 뿌리는 약용이나 종이 원료로 쓴다.
Cudrania tricuspidata belonging to the deciduous broad-leaved subfamily of Dicotyledonous nettle, Mulberry family, is also known as Goodthorn Tree. It grows in the foothills and near the village. The branches have thorns, and the leaves are divided into three branches, and the edges are flat and egg-shaped. The three-branched leaf is dull at the end and rounded at the bottom. The egg-shaped leaves are sharp at the ends and bottom, 6-10cm long, 3-6cm wide, with fine hairs on the surface, and villi on the back are entangled with each other. Petioles are 15-25mm long, with hairs. The leaves are used as a mulberry leaf substitute, the fruit can be eaten, jam or soaked, and the bark and roots are used as medicinal or paper ingredients.

꾸지뽕나무의 뿌리껍질, 나무질부, 나무껍질 및 잎에는 인체에 유효한 다양한 성분이 포함되어 있어서, 전래로부터 꾸지뽕나무는 그 뿌리, 껍질, 줄기, 잎, 나무껍질, 열매 등 부위에 따라 혈압강하제, 결핵치료제, 해열제, 건해제, 거담제, 이뇨제, 지혈제, 거풍제 등의 약재로 이용 되었으며, 항진균제로서 무좀에 사용하고 소화기관의 허약에 의한 만성소화불량에 이용되고 있다. 또한 줄기 껍질에는 폐암, 대장암, 피부암, 자궁암 등에 효과가 좋은 성분이 다량 함유되어 있다고 보고되고 있다. 꾸지뽕나무는 항암효과가 있는 것으로 알려진 플라노보이드를 함유하고 있어서 약재로 동의보감, 약성감, 본초강목 등에서 고대로부터 널리 알려져 있다.
Root bark, tree bark, bark and leaves of Cudrania japonica contain various ingredients effective for the human body. From now on, Cudrania japonica is a blood pressure lowering agent, tuberculosis depending on the root, bark, stem, leaf, bark, fruit, etc. It has been used as a medicine for antipyretics, antipyretics, expectorants, diuretics, hemostatics, and antiperspirants. It is used for athlete's foot as an antifungal agent and for chronic dyspepsia due to weakness of digestive organs. In addition, stem bark has been reported to contain a large amount of ingredients effective in lung cancer, colon cancer, skin cancer, uterine cancer. Cudrania japonica is known as anti-cancer effect, because it contains a flanovoid known as an anticancer effect, synonymous bogam, weakness, herbal wood, etc. from ancient times.

최근 지속적으로 꾸지뽕나무로부터의 추출물을 이용한 다양한 연구가 지속되고 있으며, 논문 J East Asian Soc Dietary Life, 18(4): 516~523 (2008)에서는 꾸지뽕잎으로 제조한 덖음차와 발효차의 항당뇨 효과를 기재하고 있고 대한민국 공개특허 제2012-26992호에는 꾸지뽕 추출물 및 의이인 추출물을 포함하는 비만과 당뇨 억제 효과를 개시하고 있다. 또한, 대한민국 등록특허 제10-815212호에서는 혈당 및 체중을 조절할 수 있는 꾸지뽕잎 추출물과 난소화성 말토덱스트린의 배합물이 제공되고 있다. 하지만, 이러한 문헌에 나타난 혈당강하 효과는 비교적 미비한 효과를 나타내고 있다. 따라서 현재에도 꾸지뽕을 이용한 다양한 연구가 진행되고 있다.
Recently, various studies using extracts from courageous tree have been continuously conducted, and in the paper J East Asian Soc Dietary Life, 18 (4): 516 ~ 523 (2008), the anti-diabetic effect of tea and fermented tea made from coupe leaf Korean Patent Laid-Open Publication No. 2012-26992 discloses an effect of inhibiting obesity and diabetes, including kkujippong extract and Euiyiin extract. In addition, the Republic of Korea Patent No. 10-815212 is provided with a combination of kkujippong leaf extract and indigestible maltodextrin that can control blood sugar and weight. However, the hypoglycemic effect shown in these documents shows a relatively insignificant effect. Therefore, a variety of researches are still underway using coujippong.

본 발명자들은 당뇨병 환자의 혈당을 개선할 수 있는 건강기능식품 조성물을 연구하던 중에 돼지감자 및 꾸지뽕을 혼합한 추출물은 함량을 각각의 반량 정도 함유하더라도 상승 작용에 의해 혈당강하에 현저히 탁월한 효과를 나타냄을 확인하고 본 발명을 완성하게 되었다.
The inventors of the present invention while studying a health functional food composition that can improve the blood sugar of diabetics, even if the extract of pig potato and kkujippong contains about half each of the content shows a significant effect on the blood sugar drop by synergism It confirmed and completed this invention.

본 발명은 혈당강하에 효능이 있는 돼지감자 및 꾸지뽕잎의 복합추출물 및 이를 이용한 건강기능식품 조성물을 제공하는 것이다.
The present invention is to provide a composite extract of swine potato and cooji mulberry leaves effective in lowering blood sugar and health functional food composition using the same.

상기와 같은 목적을 달성하기 위하여, 본 발명은 건조된 돼지감자 및 꾸지뽕잎의 복합추출물을 제공한다.
In order to achieve the above object, the present invention provides a composite extract of dried pork potato and kkujippong leaves.

또한, 본 발명에 따른 복합추출물을 함유하는 건강기능식품 조성물을 제공한다.
In addition, it provides a health functional food composition containing a complex extract according to the present invention.

이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.

본 발명은 건조된 돼지감자 및 꾸지뽕잎을 혼합하고 추출하여 복합추출물을 제조한다. 본 발명에서 복합추출물을 제조하기 위해 사용한 건조된 돼지감자 및 꾸지뽕잎의 함량은 각각 의 함량에 비하여 3/10 내지 7/10의 양을 함유하며, 그 함량비는 3:7 내지 7:3 중량%이고, 가장 바람직한 복합추출물의 함량은 돼지감자 및 꾸지뽕잎이 4:6 내지 6:4 중량%을 함유하여 제조하는 것이다.
The present invention is to prepare a composite extract by mixing and extracting dried pork potato and kkujippong leaves. In the present invention, the contents of the dried pork potato and Cudrania leaf used to prepare the complex extract contain an amount of 3/10 to 7/10 relative to the respective content, and the content ratio is 3: 7 to 7: 3 weight %, The most preferred content of the composite extract is to prepare the pork potato and kkujippong leaves containing 4: 6 to 6: 4% by weight.

본 발명에 따른 추출방법은 한약제제 및 천연물 사용시 제조하는 통상적인 추출방법을 사용하여 제조 할 수 있다. 추출 방법으로는 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출 및 증기 추출로 이루어진 군으로부터 선택된 어느 하나인 것이 바람직하나 이에 한정되지 않는다. 바람직한 추출방법은 열수 추출방법이다.
Extraction method according to the invention can be prepared using conventional extraction methods prepared when using herbal medicines and natural products. The extraction method is preferably any one selected from the group consisting of hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction and steam extraction, but is not limited thereto. Preferred extraction method is hot water extraction method.

본 발명은 돼지감자 및 꾸지뽕잎을 3:7 내지 7:3 중량%, 바람직하게는 복합추출물의 함량은 돼지감자 및 꾸지뽕잎이 4:6 내지 6:4 중량%을 함유하며, 약학적으로 허용 가능한 담체, 희석제 또는 부형제를 포함하여 당뇨병의 예방 및 치료용 제제로 제제화 할 수 있다.
The present invention is 3: 7 to 7: 3% by weight of pig potatoes and Cudrania leaves, preferably the content of the composite extract contains 4: 6 to 6: 4% by weight of pig potatoes and Cudrania leaves, pharmaceutically acceptable Possible carriers, diluents or excipients may be formulated into preparations for the prevention and treatment of diabetes.

본 발명에 따른 제제화에 필요한 생약 추출물은 조성물 총 중량에 대하여 상기 추출물을 0.01 내지 80%, 바람직하게는 1 내지 50% 중량으로 포함한다.
The herbal extract required for formulation according to the present invention comprises 0.01 to 80%, preferably 1 to 50% by weight of the extract relative to the total weight of the composition.

본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아고무, 알지네이트, 젤라틴, 칼슘포스페이트, 칼슘실리케이트, 셀룰로즈, 메틸셀룰로즈, 미정질셀룰로스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘스테아레이트 및 광물유를 들 수 있다.
Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

또한, 본 발명의 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.
In addition, the compositions of the present invention may be used in the form of oral dosage forms, external preparations, suppositories, or sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods. Can be.

상세하게는, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 생약 복합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.
More specifically, when formulating the composition, it can be prepared using a diluent or an excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. Can be prepared by mixing. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, syrups and the like, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used diluents such as water and liquid paraffin . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

본 발명의 복합추출물은 환자의 나이, 성별, 체중에 따라 달라질 수 있으나, 일반적으로 0.01 내지 10g/㎏의 양, 바람직하게는 1 내지 5g/㎏의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 또한 그 투여량은 투여경로, 질병의 정도, 성별, 체중, 나이, 건강상태, 식이, 투여시간, 투여방법, 배설율 등에 따라서 증감될 수 있다. 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.
The complex extract of the present invention may vary depending on the age, sex, and weight of the patient, but in general, an amount of 0.01 to 10 g / kg, preferably 1 to 5 g / kg, may be administered once or several times a day. have. In addition, the dosage may be increased or decreased depending on the route of administration, degree of disease, sex, weight, age, health condition, diet, administration time, administration method, excretion rate, and the like. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.

또한, 본 발명에 따른 복합추출물을 함유하는 당뇨환자를 위한 건강기능식품은 상기 제조한 복합추출물을 주성분으로 함유하고, 상기한 성분 외에 식품학적으로 허용되는 첨가물이나 부형제를 포함할 수 있다. 이 때 식품학적으로 허용되는 첨가물과 부형제로는 비타민 B1, 비타민 B2, 비타민 C, 비타민 B6, 니코틴산아미드, 구연산, 액상과당, 스테비오사이드, 말토덱스트린, 마뉴카벌꿀, 사과농축액, 락추로오스 분말, 실리코알루민산나트륨, 자당지방산에스테르, 히드록시프로필메칠셀룰로오스, 글리세린지방산에스테르, 산화아연, 베타-시클로덱스트린 등이 있다.
In addition, the health functional food for diabetic patients containing the complex extract according to the present invention contains the prepared complex extract as a main ingredient, and may include food additives or excipients that are acceptable in addition to the above components. At this time, food additives and excipients which are acceptable in the food industry include vitamin B1, vitamin B2, vitamin C, vitamin B6, nicotinamide, citric acid, liquid fructose, stevioside, maltodextrin, manuka honey, apple concentrate, lacchurose powder, Sodium silicate, sucrose fatty acid ester, hydroxypropyl methyl cellulose, glycerin fatty acid ester, zinc oxide, beta-cyclodextrin and the like.

본 발명의 복합추출물은 통상적으로 알려진 방법에 의하여 다양한 형태의 건강기능식품으로 제조될 수 있고, 예를 들면 액제(음료, 파우치), 정제, 환제, 경질캡슐제, 연질캡슐제, 과립제 등으로 제조될 수 있다.
The complex extract of the present invention can be prepared in various forms of health functional food by a commonly known method, for example, liquid (beverage, pouch), tablets, pills, hard capsules, soft capsules, granules, etc. Can be.

본 발명에 따른 돼지감자 및 꾸지뽕잎의 복합추출물은 혈당강하에 탁월한 효능이 있어, 당뇨병 치료제로 개발 될 수 있을 뿐만 아니라, 당뇨 환자의 혈당을 개선하기 위한 건강기능식품 조성물로 유용하게 사용할 수 있다.
The complex extract of pork potato and jjippong leaf according to the present invention has excellent efficacy in lowering blood sugar, and can be used as a health functional food composition for improving blood sugar of diabetics as well as being developed as a diabetes treatment.

이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.

단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.
However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the present invention is not limited to the following Examples and Experimental Examples.

<< 실시예Example 1>  1> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(5:5 중량%)의 제조 Preparation of Complex Extract (5: 5 wt%)

돼지감자 2kg을 정제수로 세척한 후, 세절기를 이용하여 10~15mm로 얇게 세절하고 60℃에서 약 1시간 건조 시켰다. 별로도 꾸지뽕잎 2kg을 정제수로 세척한 후 60℃에서 약 1시간 건조 시켰다. 건조된 돼지감자 500g 및 꾸지뽕잎 500g(주성분 중량 대비=5:5 중량 %)에 중량 대비 8배량의 정제수를 첨가하고, 95℃에서 5시간 동안 2회 추출을 실시한 후 여과하여 40 Brix 로 감암 농축하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.
After washing 2kg of pork potatoes with purified water, thinly sliced into 10 ~ 15mm using a washing machine and dried at 60 ℃ for about 1 hour. Separately kkujippong 2kg was washed with purified water and dried at 60 ℃ for about 1 hour. 500g of dried pork potato and 500g of Cudrania leaves (5: 5% by weight of main ingredient) were added with 8 times the amount of purified water, extracted twice at 95 ° C for 5 hours, filtered and concentrated to 40 Brix. To prepare a pig and potato kkujippong complex extract.

<< 실시예Example 2>  2> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(3:7 중량%)의 제조 Preparation of Complex Extract (3: 7 wt%)

실시예 1과 동일한 방법으로 건조시킨 돼지감자 300g 및 꾸지뽕잎 700g(주성분 중량 대비=3:7)을 배합하여 실시예 1의 방법과 동일하게 제조하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.The same method as in Example 1 was prepared by combining 300 g of dried pork potatoes and 700 g of Cudrania leaf (compare the main component weight = 3: 7) in the same manner as in Example 1, thereby preparing a complex extract of Porcine Potato and Cudrania leaf.

<< 실시예Example 3>  3> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(4:6 중량%)의 제조 Preparation of Complex Extract (4: 6 wt%)

실시예 1과 동일한 방법으로 건조시킨 돼지감자 400g 및 꾸지뽕잎 600g(주성분 중량 대비=4:6)을 배합하여 실시예 1의 방법과 동일하게 제조하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.In the same manner as in Example 1, 400 g of dried pork potato and 600 g of Cudrania leaf (compared to the main component weight = 4: 6) were prepared in the same manner as in Example 1, thereby preparing a composite extract of Porcine Potato and Cudrania leaf.

<< 실시예Example 4>  4> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(6:4 중량%)의 제조 Preparation of Complex Extract (6: 4 wt%)

실시예 1과 동일한 방법으로 건조시킨 돼지감자 600g 및 꾸지뽕잎 400g(주성분 중량 대비=6:4)을 배합하여 실시예 1의 방법과 동일하게 제조하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.In the same manner as in Example 1, the dried pork potato 600g and 400g Cudrania leaf 400g (compared to the main component weight = 6: 4) was prepared in the same manner as in Example 1 to prepare a pig and Cudrania leaf composite extract.

<< 실시예Example 5>  5> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(7:3 중량%)의 제조 Preparation of Complex Extract (7: 3 wt%)

실시예 1과 동일한 방법으로 건조시킨 돼지감자 700g 및 꾸지뽕잎 300g(주성분 중량 대비=7:3)을 배합하여 실시예 1의 방법과 동일하게 제조하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.
In the same manner as in Example 1 700g dried pork potato and 300g kkujippong leaf 300g (compared to the main component weight = 7: 3) was prepared in the same manner as in Example 1 to prepare a pig extract and kkujippong leaves complex extract.

<< 비교예Comparative Example 1> 돼지감자 추출물의 제조 1> Preparation of Pork Potato Extract

돼지감자 2kg을 정제수로 세척한 후, 세절기를 이용하여 10 ~ 15mm로 얇게 세절하고 50 ~ 60℃의 온도를 갖는 건조기에서 약 1시간 건조 시켰다. 건조된 돼지감자 1kg에 중량 대비 5배량의 정제수를 첨가하고, 95℃에서 4 ~ 5시간 동안 2회 추출을 실시한 후 여과하여 40 Brix 로 감암 농축하여 돼지감자 추출물을 제조하였다.
After washing 2kg of pork potatoes with purified water, thinly sliced into 10 ~ 15mm using a washing machine and dried for about 1 hour in a dryer having a temperature of 50 ~ 60 ℃. 5 kg purified water was added to 1 kg of dried pork potatoes, extracted twice at 95 ° C. for 4 to 5 hours, filtered and concentrated to 40 Brix to prepare pork extract.

<< 비교예Comparative Example 2>  2> 꾸지뽕잎Cedar leaf 추출물의 제조 Preparation of extract

꾸지뽕잎 2kg을 정제수로 세척한 후 50 ~ 60℃의 온도를 갖는 건조기에서 약 1시간 건조 시켰다. 건조된 꾸지뽕잎 1kg에 중량 대비 5배량의 정제수를 첨가하고 95℃에서 3 ~ 4시간 동안 2회 추출을 실시한 후 여과하여 40 Brix 로 감암 농축하여 꾸지뽕잎 추출물을 제조하였다.
After washing with 2kg of kkujippong leaves with purified water it was dried for about 1 hour in a dryer having a temperature of 50 ~ 60 ℃. 5 kg of purified water was added to 1 kg of dried Cudrania leaf, and extracted twice at 3 ° C. for 3-4 hours at 95 ° C., followed by filtration and concentrated to 40 Brix to prepare Cudrania leaf extract.

본 발명에 의해 제조된 돼지감자와 꾸지뽕잎 복합추출물의 실시예 1 내지 5 및 비교예 1 및 2를 통해 제조된 돼지감자 추출물 및 꾸지뽕잎 추출물의 주성분 함량비를 하기 표 1에 나타내었다.
Table 1 shows the main component content ratios of the pork potato extract and Cudrania leaf extract prepared by Examples 1 to 5 and Comparative Examples 1 and 2 of the pork potato and Cudrania leaf composite extract prepared by the present invention.

Figure 112012043861953-pat00001
Figure 112012043861953-pat00001

본 발명을 통해 제조된 돼지감자와 꾸지뽕잎 복합추출물인 각각의 실시예 1 내지 5 및 돼지감자 추출액의 비교예 1과 꾸지뽕잎 추출물인 비교예 2를 하기의 실험예를 통해 혈당강하 효과를 확인하였다.
The blood glucose lowering effect was confirmed through the following experimental examples of Comparative Examples 1 and Comparative Example 2 of the Pork Potato and Cudrania leaf complex extract prepared according to the present invention, Examples 1 to 5 and the Porcine Potato Extract extract. .

<< 실험예Experimental Example 1>  1> 혈당 강하 효과 시험Hypoglycemic effect test

1. 실험동물1. Experimental animals

실험동물은 약 4주령이 된 Sparague-Dawley 종 흰쥐 수컷을 7일간 고형사료(pellet)로 사육하면서 환경에 적응시켰다. 1주일간 안정시킨 후 6주령(체중:150~170g)이 되었을 때 실험동물을 난괴법(randomized complete block design)에 의하여 7마리를 1개군으로 하여 9개군으로 나누고 1군의 정상군과 8군의 당뇨유발군으로 분리하였다. 즉, 당뇨를 유발하지 않고 증류수를 자유 음수시킨 normal군, STZ로 당뇨를 유발한 후 증류수를 자유 음수시킨 STZ-control군, 당뇨유발 흰쥐에 돼지감자 추출물을 투여한 군(HT군, 비교예 1), 당뇨유발 흰쥐에 꾸지뽕잎 추출물(CT군, 비교예 2)을 투여한 군, 당뇨유발 흰쥐에 주성분 배합 비율별로 혼합한 돼지감자와 꾸지뽕잎 복합추출물을 자유 음수시킨 HCT-1군(3:7, 실시예 2), HCT-2군(4:6, 실시예 3), HCT-3군(5:5, 실시예 1), HCT-4군(6:4, 실시예 4), HCT-5군(7:3, 실시예 5)으로 구분하여 사육하였다.
The experimental animals were adapted to the environment by breeding male Sparague-Dawley rats, about 4 weeks old, as pellets for 7 days. After 6 weeks of stabilization for 1 week (weight: 150-170g), the experimental animals were divided into 9 groups with 1 group by the randomized complete block design. Diabetic isolates. That is, the normal group free of distilled water without causing diabetes, the STZ-control group free of negative distilled water after inducing diabetes with STZ, the group of pig potato extracts administered to diabetic rats (HT group, Comparative Example 1 ), HCT-1 group free of negatively mixed pig potato and Cudrania leaf complex extracts mixed with the main components in the diabetic rats (C group, Comparative Example 2) administration group, diabetic rats. 7, Example 2), HCT-2 group (4: 6, Example 3), HCT-3 group (5: 5, Example 1), HCT-4 group (6: 4, Example 4), HCT -5 groups (7: 3, Example 5) were divided and bred.

2. 스트렙토조토신(STZ)에 의한 당뇨유발2. Diabetes Induction by Streptozotocin (STZ)

당뇨를 유발시키기 위하여 16시간 실험동물을 절식시킨 후, 췌장의 β-세포만을 특이적으로 작용하여 다른 기관에 영향을 미치지 않는다고 알려진 STZ(Sigma Chemical Co.)(Wright&Lacy 1988)을 pH4.5의 0.01M citrate buffer에 45mg/kg B.W.농도로 녹여 꼬리 정맥에 주사하였다. 정상군은 동량의 0.01M citrate buffer 용액을 주사하였다. STZ 을 주사한 후 약 7시간이 지나면 혈당량이 급격히 감소하고 인슐린 농도가 상승하다가 서서히 혈당이 상승되고 β-세포의 파괴로 인하여 인슐린 농도가 감소되며 48시간이 경과된 후에는 고혈당 상태가 지속되므로, 주사 후 48시간 후에 꼬리 정맥에서 혈액을 채취하여 혈당 측정기로 혈당 농도를 측정하여 혈당 농도가 300mg/㎗이상인 것을 당뇨가 유발된 것으로 확인하여 실험에 사용하였다.
After fasting the experimental animals for 16 hours to induce diabetes, STZ (Sigma Chemical Co.) (Wright & Lacy 1988), which is known to specifically act on only the β-cells of the pancreas and does not affect other organs, has a pH of 0.01. It was dissolved in 45 mg / kg BW concentration in citrate buffer and injected into the tail vein. Normal group was injected with the same amount of 0.01M citrate buffer solution. About 7 hours after the injection of STZ, blood glucose level rapidly decreases, insulin concentration rises, then blood glucose level rises, insulin concentration decreases due to the destruction of β-cells, and hyperglycemic state persists after 48 hours. After 48 hours after injection, blood was collected from the tail vein and the blood glucose level was measured using a blood glucose meter to determine that the blood glucose concentration was 300 mg / ㎗ or more, and it was used in the experiment.

3. 실험식이3. Experimental diet

식이 섭취량은 매일 일정한 시간에 칭량하여 1일 섭취한 식이의 양을 측정하고 1주일 단위로 주당 1일 평균 식이 섭취량을 구하였으며, 체중은 1주일에 한번씩 일정한 시간에 동물용 체중계로 측정하였으며, 식이효율(feed efficiency ratio:FER)은 체중 증가량을 식이섭취량으로 나누어서 구하였다.
The dietary intake was measured at a certain time every day to measure the amount of diet consumed per day, and the average daily intake per week was obtained on a weekly basis, and the weight was measured on an animal scale at a regular time once a week. The feed efficiency ratio (FER) was obtained by dividing weight gain by dietary intake.

4. 혈중 포도당 측정4. Blood glucose measurement

혈중 포도당 농도는 미정맥으로부터 체혈한 핼액을 Pre-cision Q·I·D ®Blood Glucose Monitoring System (Medisense Inc. USA)으로 직접 측정하여 각각의 실시예 1 내지 5 및 비교예 1 내지 2에 대한 혈당강하 효과를 하기 표 2에 나타내었다.
Blood glucose concentrations of the glucose haelaek chehyeol from a vein in US Pre-cision Q · I · D ® Blood Glucose Monitoring System embodiment (Medisense Inc. USA) by direct measurement of each of Examples 1 to 5 and Comparative Examples 1 to 2 The dropping effect is shown in Table 2 below.

Figure 112012043861953-pat00002
Figure 112012043861953-pat00002

상기 표 2에서 알 수 있는 바와 같이, 돼지감자 및/또는 꾸지뽕잎 추출물을 함유하는 모든 실험군은 정상군에 비하여 높은 혈당 수준을 나타내었다. 실험 3주까지는 STZ-control군과 실험식이(추출물)를 투여한 실험군 사이에 유의적인 차이는 나타나지 않았으나, 실험 4주 후부터 시작하여 STZ-control군과 비교하여 STZ-contro+HT군, STZ-control+CT군, HCT-1 내지 5군 모두 혈당치가 감소됨을 확인할 수 있었다.
As can be seen in Table 2, all experimental groups containing pig potato and / or kkujippong leaf extract showed a higher blood sugar level than the normal group. There was no significant difference between the STZ-control group and the experimental group (extract) administered up to 3 weeks, but after 4 weeks, the STZ-contro + HT and STZ-control groups were compared with the STZ-control group. In the + CT group, HCT-1 to 5 groups, it was confirmed that the blood glucose level was reduced.

하지만, 돼지감자 또는 꾸지뽕잎 추출물을 단독으로 함유하는 비교예 1 및 비교예 2에서 제조된 단일추출물 투여군(STZ-contro+HT군, STZ-control+CT군)에서는 혈당치가 감소하는 것은 확인 되었지만 STZ-control군과 비교하여 현저하게 감소하는 효과는 아닌 것을 알 수 있다.
However, in the single extract administration group (STZ-contro + HT group, STZ-control + CT group) prepared in Comparative Example 1 and Comparative Example 2 containing porcine potato or Cudrania leaf extract alone, it was confirmed that the blood glucose level was decreased. It can be seen that the effect is not significantly reduced compared to the -control group.

반면에, 본 발명의 실시예 1 내지 5를 통해 제조된 돼지감자 및 꾸지뽕잎 복합 추출물의 경우에는 돼지감자 또는 꾸지뽕잎 단독 추출물 보다 각각 3/10 내지 7/10 중량부 감소된 양을 혼합하여 돼지감자 또는 꾸지뽕잎 추출물의 양과 동일하게 혼합하여 투여한 것임에도 불구하고 STZ-control군 및 비교예 1 및 비교예 2에서 제조된 단일추출물 투여군(STZ-contro+HT군, STZ-control+CT군)과 비교하여 현저하게 감소되는 것을 확인 할 수 있다. 특히 본 발명의 실시예 1 및 실시예 3 내지 4에서 제조한 돼지감자 및 꾸지뽕잎의 주성분 함량이 돼지감자 또는 꾸지뽕잎 단독 추출물 보다 각각 2/50 내지 3/5 중량부 감소된 양을 혼합하여 4:6 내지 6:4에 해당하는 복합추출물을 투여한 HCT-2 내지 4군에서는 현저한 혈당 강하 효과를 나타내었다.
On the other hand, in the case of the porcine potato and kkujippong leaf complex extract prepared in Examples 1 to 5 of the present invention, the mixture by reducing the amount of 3/10 to 7/10 parts by weight than the pig potato or kkujippong leaf alone extract, respectively Despite being administered in the same amount as the amount of potato or Cudrania leaf extract, the STZ-control group and the single extract administration group prepared in Comparative Examples 1 and 2 (STZ-contro + HT group, STZ-control + CT group) It can be seen that it is significantly reduced in comparison with. In particular, the main components of the pork potato and kkujippong leaves prepared in Examples 1 and 3 to 4 of the present invention by mixing 2/50 to 3/5 parts by weight of the reduced amount of each compared to the pig potato or kkujippong leaves alone extract 4 In the HCT-2 to 4 groups administered the complex extract corresponding to: 6 to 6: 4, there was a significant hypoglycemic effect.

따라서 본 발명은 돼지감자 및 꾸지뽕잎의 중량 기준(%)으로 4 : 6 내지 6 : 4의 복합비율을 가지는 복합 추출물이 돼지감자 또는 꾸지뽕잎 각각의 추출물에 비하여 혈당강하에 탁월한 효과가 나타내어 당뇨병 치료제로 개발 될 수 있을 뿐만 아니라, 당뇨병 관련 질환의 건강기능식품 조성물로 유용하게 사용할 수 있다.
Therefore, the present invention exhibits an excellent effect on the hypoglycemic effect of the complex extract having a complex ratio of 4: 6 to 6: 4 on the basis of the weight (%) of the pork potato and cooji mulberry leaves compared to the respective extracts of pig potato or coo zippong leaves Not only can be developed, it can be usefully used as a dietary supplement composition of diabetes-related diseases.

하기 제조예는 본 발명의 돼지감자 및 꾸지뽕잎의 복합추출물을 함유하는 여러 제형의 예를 나타낸 것이며, 아래의 제제예는 본 발명을 예시하는 것일 뿐, 이에 의해 본 발명의 내용이 제한되는 것은 아니다.
The following preparation examples show examples of various formulations containing the complex extract of pork potato and cooji mulberry leaves of the present invention, the following preparation examples are merely to illustrate the present invention, thereby not limiting the contents of the present invention .

<제제예 1> 산제의 제조Preparation Example 1 Preparation of Powder

실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1

옥수수전분 100mgCorn Starch 100mg

유 당 100mgLactose 100mg

탈 크 10mgTalc 10mg

상기의 성분들을 혼합하고 기밀 포에 충진 하여 산제를 제조한다.
The above ingredients are mixed and filled in airtight cloth to prepare a powder.

<제제예 2> 정제의 제조&Lt; Formulation Example 2 > Preparation of tablet

실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1

옥수수전분 100mgCorn Starch 100mg

유 당 100mgLactose 100mg

스테아린산 마그네슘 2mg2 mg magnesium stearate

상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

<제제예 3> 캡슐제의 제조&Lt; Formulation Example 3 > Preparation of capsules

실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1

유 당 50mgLactose 50mg

스테아린산 마그네슘 1mg1 mg magnesium stearate

상기의 성분들을 혼합한 후 통상의 캡슐제의 제조방법에 따라서 타정하여 젤라틴 캡슐제에 충진 하여 제조한다.
After mixing the above components is compressed into a gelatin capsule prepared by the compression method according to the conventional manufacturing method of the capsule.

<제제예 4> 액제의 제조Preparation Example 4 Preparation of Liquid

실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1

이성화당 10g10g per isomerization

서 당 10g10g per book

레몬향 적량Lemon incense quantity

정제수 적량Purified water quantity

통상의 액제의 제조방법에 따라서 정제수에 각각의 성분을 가하고 용해시키고 레몬향을 적량 가한 다음 정제수를 가하여 전체를 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜서 액제를 제조한다.
According to the conventional method for preparing a liquid solution, each component is added to the purified water, dissolved, and lemon flavor is added, and then purified water is added to adjust the total amount to 100 ml, and then filled into a brown bottle to prepare a liquid solution.

<제제예 5> 건강 식품의 제조Preparation Example 5 Preparation of Health Food

실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1

비타민 혼합물 적량Vitamin mixture quantity

비타민 A 아세테이트 70 ㎍70 [mu] g of vitamin A acetate

비타민 E 1.0 ㎎Vitamin E 1.0 mg

비타민 B1 0.13 ㎎0.13 mg vitamin B1

비타민 B2 0.15 ㎎0.15 mg of vitamin B2

비타민 B6 0.5 ㎎0.5 mg vitamin B6

비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12

비타민 C 10 ㎎10 mg vitamin C

비오틴 10 ㎍Biotin 10 μg

니코틴산아미드 1.7 ㎎Nicotinic acid amide 1.7 mg

엽산 50 ㎍50 ㎍ of folic acid

판토텐산 칼슘 0.5 ㎎Calcium pantothenate 0.5 mg

무기질 혼합물 적량Mineral mixture quantity

황산제1철 1.75 ㎎1.75 mg of ferrous sulfate

산화아연 0.82 ㎎0.82 mg of zinc oxide

탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg

제1인산칼륨 15 ㎎15 mg of potassium phosphate monobasic

제2인산칼슘 55 ㎎Secondary calcium phosphate 55 mg

구연산칼륨 90 ㎎Potassium citrate 90 mg

탄산칼슘 100 ㎎100 mg of calcium carbonate

염화마그네슘 24.8 ㎎24.8 mg of magnesium chloride

상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.
The composition ratio of the above-mentioned vitamin and mineral mixture is composed of a relatively suitable ingredient suitable for health food as a preferred example, but the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method, and then granulated. It can be prepared and used in the manufacture of health food compositions according to conventional methods.

<제제예 6> 건강 음료의 제조Preparation Example 6 Preparation of Healthy Drinks

실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1

강활 추출물 1000 ㎎Revitalization extract 1000 mg

구연산 1000 ㎎Citric acid 1000 mg

올리고당 100 g100 g of oligosaccharide

매실농축액 2 gPlum concentrate 2 g

타우린 1 gTaurine 1 g

정제수를 가하여 전체 900 ㎖Purified water was added to a total of 900 ml

통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
After mixing the above components in accordance with a conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions. Although the composition ratio is a composition that is relatively suitable for preference beverages as a preferred example, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, use purpose.

이와 같이 본 발명은 돼지감자 및 꾸지뽕잎의 복합추출물을 함유하는 각종 식품류 및 음료류를 제조함으로서 혈당강하 효과가 기대되는 기능성 식품을 제공할 수 있다.As such, the present invention can provide a functional food that is expected to have a hypoglycemic effect by preparing various foods and beverages containing a complex extract of pork potato and cuddle mulberry leaf.

Claims (7)

삭제delete 돼지감자(Helianthus tuberous) 및 꾸지뽕잎(Cudrania tricuspidata)이 3:7 내지 7:3 중량비로 혼합된 혈당강하용 복합추출물.
Porcine potato ( Helianthus tuberous ) and Cudrania tricuspidata ( Cudrania tricuspidata ) is a hypoglycemic complex extract mixed in a 3: 7 to 7: 3 weight ratio.
제 2 항에 있어서, 돼지감자 및 꾸지뽕잎은 4:6 내지 6:4의 중량비로 혼합되는 것을 특징으로 하는 복합추출물.
The complex extract according to claim 2, wherein the pork potato and cuddle leaves are mixed in a weight ratio of 4: 6 to 6: 4.
제 2 항에 있어서, 돼지감자 및 꾸지뽕잎 추출물은 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출 및 증기 추출로 이루어진 군으로부터 선택된 어느 하나의 방법에 의해 추출됨을 특징으로 하는 복합추출물.
The complex extract according to claim 2, wherein the Pork Potato and Cudrania leaf extract are extracted by any one method selected from the group consisting of hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction and steam extraction.
제 4 항에 있어서, 돼지감자 및 꾸지뽕잎 추출물은 열수 추출에 의해 추출됨을 특징으로 하는 복합추출물.
The complex extract according to claim 4, wherein the Pork Potato and Cudrania leaf extract are extracted by hot water extraction.
제2항에 따른 복합추출물을 함유하는 당뇨 환자의 혈당 개선용 건강기능 식품.
Health functional food for improving blood sugar of diabetic patients containing the complex extract according to claim 2.
제2항에 따른 복합추출물을 함유하는 당뇨 환자의 혈당 개선용 건강기능 음료.Health functional beverage for improving blood sugar of diabetic patients containing the complex extract according to claim 2.
KR1020120058747A 2012-05-31 2012-05-31 Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same KR101359806B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020120058747A KR101359806B1 (en) 2012-05-31 2012-05-31 Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120058747A KR101359806B1 (en) 2012-05-31 2012-05-31 Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same

Publications (2)

Publication Number Publication Date
KR20130134882A KR20130134882A (en) 2013-12-10
KR101359806B1 true KR101359806B1 (en) 2014-02-13

Family

ID=49982436

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120058747A KR101359806B1 (en) 2012-05-31 2012-05-31 Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same

Country Status (1)

Country Link
KR (1) KR101359806B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101662281B1 (en) * 2015-11-04 2016-10-05 김태현 process of jerusalem artichoke-wild ginseng drink and jerusalem artichoke-wild ginseng drink there by the same that
KR102036962B1 (en) * 2017-02-15 2019-10-25 동신대학교산학협력단 Composition for Anti-Diabetes Using an Extract of Ecklonia cava etc.
KR101952643B1 (en) * 2017-10-26 2019-02-27 주식회사 보리로푸드시스템 Preparation method of grain noodle
KR102414431B1 (en) * 2019-10-25 2022-07-01 농업회사법인 주식회사 장수식품 A composition for improving, preventing and treating of diabetes mellitus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060041438A (en) * 2004-11-09 2006-05-12 이호운 Functional food for regulating blood sugar including yerusalem artichoke
KR100815212B1 (en) * 2006-10-09 2008-03-19 조운행 Antidiabetic and antiobese mixture of leaf extract of cudrania tricuspidata and digestion-resistant maltodextrin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060041438A (en) * 2004-11-09 2006-05-12 이호운 Functional food for regulating blood sugar including yerusalem artichoke
KR100815212B1 (en) * 2006-10-09 2008-03-19 조운행 Antidiabetic and antiobese mixture of leaf extract of cudrania tricuspidata and digestion-resistant maltodextrin

Also Published As

Publication number Publication date
KR20130134882A (en) 2013-12-10

Similar Documents

Publication Publication Date Title
CN102458434B (en) Composition for increasing the bioavailability of saponin
KR101359806B1 (en) Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same
KR101559130B1 (en) Composition comprising herbal extract for preventing or treating obesity
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
KR20140034620A (en) Composition for preventing or treating diabetbes mellitus disease containing extract of plants
KR101902932B1 (en) A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum
CN104800608A (en) Traditional Chinese herbal medicine composition with hypotensive effect and application thereof
CN107569608A (en) It is a kind of to be used for hypoglycemic pharmaceutical composition
KR101460126B1 (en) Composition for preventing and improving sex hormone-related disease and symptoms comprising dandelion extract or dandelion containing multiple extract as an active ingredient
KR101895972B1 (en) A composition for preventing or treating menopausal disorder comprising Tetragonia tetragonoides (Pall.) Kuntze extract
KR102414431B1 (en) A composition for improving, preventing and treating of diabetes mellitus
KR102292059B1 (en) Composition comprising of the extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating diabetic complication and diabetes
KR20140032961A (en) Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof
KR100543405B1 (en) Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus
KR102045847B1 (en) Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin
KR101350222B1 (en) An alcohol detoxification composition comprising fruit extract of Camellia japonica
KR100927435B1 (en) Pill type a healthy food for improving and alleviating the diabetes and preparation method thereof
KR20160059152A (en) Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component
KR20170055366A (en) A composition for preventing or treating obesity comprising taraxacum coreanum root extract
KR20200132261A (en) Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract
KR20150031373A (en) Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component
KR20200076185A (en) A composition for improving, preventing and treating of liver diseases comprising Milk thistle and onion
KR101641415B1 (en) Composition comprising the combined extracts of Phlomis umbrosa, Astragalus membranceus, Discorea japonica, Acanthpanax senticosus and Angelica gigas for stimulating bone growth
KR101077546B1 (en) A composition having antidiabetes activity consisting of Ligustrum fruit and red-ginseng Cheongkukjang powder
KR102233672B1 (en) A composition for improving, preventing and treating of diabetes mellitus comprising Milk thistle and Helianthus tuberosus

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20161123

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20180104

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20190103

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20200107

Year of fee payment: 7